Compare LYFT Inc (LYFT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Summit Therapeutics Inc — how do they compare? LYFT Inc trades at $16.16 (market cap $6.11B), while Summit Therapeutics Inc trades at $17.44 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 2.2× LYFT Inc's market cap, and LYFT Inc is more actively traded (13,504,560 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Summit Therapeutics Inc for 16 Days on average.
| LYFT | SMMT | |
|---|---|---|
Market Cap | $6.11B | $13.71B |
Volume | 13,504,560 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $24.57 | $26.38 |
52-Week Low | $12.65 | $12.43 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | $5.57B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.27, up 4.29% with bullish technical signals from moving averages and ADX indicators. The company shows remarkable financial improvement with 2025 revenue of $6.32B and net income of $2.84B, achieving a 45.02% profit margin. Recent developments include European expansion and a $272.5M legal settlement. Valuation metrics appear attractive with P/E of 2.35 and P/S of 0.96, though EV/EBITDA remains elevated at 34.55.
Lyft presents a mixed investment case with strong profitability growth offset by competitive pressures and regulatory risks. The stock trades below analyst consensus target of $18.07, offering potential upside, but faces challenges from driver classification lawsuits and market saturation concerns. Recent earnings misses and high RSI levels suggest near-term volatility despite positive cash flow trends and institutional support.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
